Wanning Qiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wanning Qiao has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Yang Zhang
School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, China
2 shared publications - Chenhang Li
School of Public Health (Shenzhen) Sun Yat‐sen University Shenzhen Guangdong China
1 shared publication - Cun Ku
School of Public Health (Shenzhen) Sun Yat‐sen University Shenzhen Guangdong China
1 shared publication - Dong Liang
School of Agriculture and Biotechnology
1 shared publication - Gundala Venkata Naveen Kumar
Aging Institute of UPMC University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA
1 shared publication Hanxiao Feng
School of Public Health (Shenzhen), Sun Yat-Sen University, Shenzhen, Guangdong, China
1 shared publication
Latest Publications
- Open Access
- 2 October 2026
- Published by Wiley in British Journal of Pharmacology
Inhibition of the NR4A1‐mediated cell cycle checkpoint enhances hyperplastic adipogenesis and glucose homeostasis in obesity
Background and Purpose: The nuclear receptor NR4A1 is a critical node in transcriptional circuits for metabolic adaptation, yet its role in adipocyte progenitor (AP) fate and proliferation is unclear. We sought to define how NR4A1 governs early adipogenesis and adipose tissue plasticity. Experimental Approach: Doxycycline‐inducible NR4A1‐overexpressing and NR4A1‐deficient 3T3‐L1 models were used to assess lipid accumulation, mitotic clonal expansion (MCE), and cell‐cycle dynamics. Multiomics integration (RNA‐seq and chromatin assays) identified NR4A1 targets. The functionality of two lead candidates, ANLN and CDC20, was tested by genetic knockdown and pharmacological inhibition. Diet‐induced obese mice received the NR4A1 antagonist C‐DIM8 alone or combined with the PPARγ agonist rosiglitazone to evaluate adipose expansion and metabolic outcomes. Key Results: NR4A1 exerted a stage‐specific inhibitory effect during early differentiation, reducing expression of canonical adipogenic markers and lipid accumulation. Integrative transcriptomic and chromatin analyses identified Anln and Cdc20 as direct NR4A1 targets essential for MCE. Depletion of either gene phenocopied NR4A1 overexpression, inducing G2/M arrest and blunting of adipogenesis. Pharmacological CDC20 inhibition with Apcin suppressed preadipocyte proliferation and differentiation in a dose‐dependent manner. Importantly, in a diet‐induced obese mouse model, combined treatment with the NR4A1 antagonist C‐DIM8 and the PPARγ agonist rosiglitazone promoted AP proliferation, hyperplastic adipose tissue expansion, and improved glucose tolerance. Conclusions and Implications: NR4A1 functions as a transcriptional gatekeeper of adipogenic initiation by restraining the Anln / Cdc20 cell‐cycle program. Pharmacological modulation of the NR4A1–cell‐cycle axis, particularly alongside PPARγ activation, may offer a strategy to augment adipose tissue plasticity and metabolic resilience in obesity.
- 2 October 2026
- Published by Wiley in British Journal of Pharmacology
Open AccessInhibition of the NR4A1‐mediated cell cycle checkpoint enhances hyperplastic adipogenesis and glucose homeostasis in obesity
Background and Purpose: The nuclear receptor NR4A1 is a critical node in transcriptional circuits for metabolic adaptation, yet its role in adipocyte progenitor (AP) fate and proliferation is unclear. We sought to define how NR4A1 governs early adipogenesis and adipose tissue plasticity. Experimental Approach: Doxycycline‐inducible NR4A1‐overexpressing and NR4A1‐deficient 3T3‐L1 models were used to assess lipid accumulation, mitotic clonal expansion (MCE), and cell‐cycle dynamics. Multiomics integration (RNA‐seq and chromatin assays) identified NR4A1 targets. The functionality of two lead candidates, ANLN and CDC20, was tested by genetic knockdown and pharmacological inhibition. Diet‐induced obese mice received the NR4A1 antagonist C‐DIM8 alone or combined with the PPARγ agonist rosiglitazone to evaluate adipose expansion and metabolic outcomes. Key Results: NR4A1 exerted a stage‐specific inhibitory effect during early differentiation, reducing expression of canonical adipogenic markers and lipid accumulation. Integrative transcriptomic and chromatin analyses identified Anln and Cdc20 as direct NR4A1 targets essential for MCE. Depletion of either gene phenocopied NR4A1 overexpression, inducing G2/M arrest and blunting of adipogenesis. Pharmacological CDC20 inhibition with Apcin suppressed preadipocyte proliferation and differentiation in a dose‐dependent manner. Importantly, in a diet‐induced obese mouse model, combined treatment with the NR4A1 antagonist C‐DIM8 and the PPARγ agonist rosiglitazone promoted AP proliferation, hyperplastic adipose tissue expansion, and improved glucose tolerance. Conclusions and Implications: NR4A1 functions as a transcriptional gatekeeper of adipogenic initiation by restraining the Anln / Cdc20 cell‐cycle program. Pharmacological modulation of the NR4A1–cell‐cycle axis, particularly alongside PPARγ activation, may offer a strategy to augment adipose tissue plasticity and metabolic resilience in obesity.
- 23 January 2025
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 16 (3) , 1157-1168
Protective association between dietary phytosterol intake and cardiovascular health: an analysis of the UK Biobank cohort
Background: Cardiovascular diseases (CVDs) remain a leading cause of morbidity and mortality worldwide, with dietary interventions showing promise in reducing CVD risk factors. Phytosterols (PSs) in plant-based foods may reduce CVD risk by lowering low-density lipoprotein cholesterol. However, the relationship between dietary PS intake and CVD outcomes remains inconclusive. Methods: This study investigated the association between dietary PS intake and CVD outcomes, including coronary heart disease (CHD) and cardiovascular mortality, using a large cohort of 167 209 UK Biobank participants. PS intake was assessed through repeated 24 hour dietary recall data, with participants stratified into quintiles. The Cox proportional-hazards model was used to estimate hazard ratios (HRs) for CVD risk across quintiles of PS intake, adjusting for potential confounders. Restricted cubic splines were used to examine the nonlinear relationship between phytosterol intake and cardiovascular disease risk. Sensitivity and subgroup analyses explored interactions with demographic and lifestyle factors. Results: Higher dietary PS intake was significantly associated with a reduced risk of CVD events, including CHD and cardiovascular mortality. Each 100 mg increase in PS intake was linked to an 8% reduction in CVD risk (HR = 0.92, 95% CI: 0.87, 0.97). Multivariable-adjusted analyses revealed that participants in the highest quintile of PS intake had significantly lower CVD hazard ratios (HR = 0.81, 95% CI: 0.77, 0.84) compared to those in the lowest quintile. Significant inverse associations were also observed for cardiovascular mortality (HR: 0.86, 95% CI: 0.80, 0.94) and CHD (HR: 0.91, 95% CI: 0.84, 0.98). Subgroup analysis highlighted stronger inverse associations in current smokers, individuals with lower body mass index (BMI), and those with moderate to high physical activity levels, with variations observed based on dyslipidemia status. Sensitivity analyses, excluding early events and adjusting for energy intake, confirmed the robustness of the findings. Conclusions: This large cohort study provides evidence supporting the cardioprotective effects of dietary PS intake, particularly for CHD and cardiovascular mortality. Dietary PS may be considered an integral component of heart-healthy diets.
- 23 January 2025
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 16 (3) , 1157-1168
Protective association between dietary phytosterol intake and cardiovascular health: an analysis of the UK Biobank cohort
Background: Cardiovascular diseases (CVDs) remain a leading cause of morbidity and mortality worldwide, with dietary interventions showing promise in reducing CVD risk factors. Phytosterols (PSs) in plant-based foods may reduce CVD risk by lowering low-density lipoprotein cholesterol. However, the relationship between dietary PS intake and CVD outcomes remains inconclusive. Methods: This study investigated the association between dietary PS intake and CVD outcomes, including coronary heart disease (CHD) and cardiovascular mortality, using a large cohort of 167 209 UK Biobank participants. PS intake was assessed through repeated 24 hour dietary recall data, with participants stratified into quintiles. The Cox proportional-hazards model was used to estimate hazard ratios (HRs) for CVD risk across quintiles of PS intake, adjusting for potential confounders. Restricted cubic splines were used to examine the nonlinear relationship between phytosterol intake and cardiovascular disease risk. Sensitivity and subgroup analyses explored interactions with demographic and lifestyle factors. Results: Higher dietary PS intake was significantly associated with a reduced risk of CVD events, including CHD and cardiovascular mortality. Each 100 mg increase in PS intake was linked to an 8% reduction in CVD risk (HR = 0.92, 95% CI: 0.87, 0.97). Multivariable-adjusted analyses revealed that participants in the highest quintile of PS intake had significantly lower CVD hazard ratios (HR = 0.81, 95% CI: 0.77, 0.84) compared to those in the lowest quintile. Significant inverse associations were also observed for cardiovascular mortality (HR: 0.86, 95% CI: 0.80, 0.94) and CHD (HR: 0.91, 95% CI: 0.84, 0.98). Subgroup analysis highlighted stronger inverse associations in current smokers, individuals with lower body mass index (BMI), and those with moderate to high physical activity levels, with variations observed based on dyslipidemia status. Sensitivity analyses, excluding early events and adjusting for energy intake, confirmed the robustness of the findings. Conclusions: This large cohort study provides evidence supporting the cardioprotective effects of dietary PS intake, particularly for CHD and cardiovascular mortality. Dietary PS may be considered an integral component of heart-healthy diets.